EAACI Congress 2025
BackFT23 - News in hereditary angioedema management
Monday 16 Jun, 10:45 AM -
12:15 PM Glasgow, United Kingdom
Dochart 2
Flash Talks
10:45
Hereditary Angioedema with Normal C1 Inhibitor: Novel Genetic Mutations and Insights from a Large Genomic Cohort Study
10:52
Initial description of a patient with a new plasminogen mutation who exhibits symptoms consistent with hereditary angioedema
10:59
Elucidating the pathogenesis of hereditary angioedema through advanced genetic sequencing and single-cell sequencing analyses
11:06
Identification of candidate biomarkers for diagnosing and assessing the disease severity of type 2 hereditary angioedema via plasma N-glycomics
11:13
Correlation Between Subjective and Objective Disease Control in Hereditary Angioedema: Association Between the Angioedema Control Test and Attack Rate
11:20
Burnout and Stress in Angioedema Care: Insights from a Multicenter Observational Study MENPHYS
11:27
The Effect of Surgical and Interventional Procedures on Attack Frequency in Hereditary Angioedema Patients
11:34
Innovation to collect data for a national registry of patients with hereditary angioedema: the first phase of establishing the dynamic HARPE registry
11:41
Impact of Delayed Treatment of Hereditary Angioedema Attacks: Insights from Patient Surveys Across France, the United Kingdom, and the United States
11:48
Attack-free probability modeling of garadacimab long-term prophylaxis for hereditary angioedema
11:55
Safety assessment of garadacimab in clinical studies involving patients with hereditary angioedema, idiopathic pulmonary fibrosis, and COVID-19
12:02
Clinical characteristics and unmet treatment need in patients with hereditary angioedema treated with long-term prophylaxis: A real-world survey
